🇺🇸 FDA
Pipeline program

TECLISTAMAB, TECLISTAMAB

MM0125

Phase 2 small_molecule active

Quick answer

TECLISTAMAB, TECLISTAMAB for refractory/relapsed multiple myeloma is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
refractory/relapsed multiple myeloma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials